SCHEMBL6727036

SCHEMBL6727036

Cc1c(C(=O)O)c(C)n(C(C(N)=O)N2CCOCC2)c1C=C1C(=O)Nc2ccc(F)cc21

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDR P35968 9/20 0.53
▸ FLT1 P17948 2/20 0.53
▸ ALK Q9UM73 2/20 0.50
▸ PDGFRB P09619 8/20 0.49
▸ FGFR1 P11362 4/20 0.49
▸ FLT3 P36888 7/20 0.48
▸ KIT P10721 5/20 0.48
▸ TLK2 Q86UE8 3/20 0.48
▸ RIOK2 Q9BVS4 2/20 0.48
▸ TLK1 Q9UKI8 2/20 0.48
▸ PRKAA2 P54646 2/20 0.48
▸ PRKAA1 Q13131 2/20 0.48
▸ LRRK2 Q5S007 2/20 0.48
▸ BMPR1B O00238 1/20 0.48
▸ PLK4 O00444 1/20 0.48
▸ STK25 O00506 1/20 0.48
▸ CIT O14578 1/20 0.48
▸ RIOK3 O14730 1/20 0.48
▸ CHEK1 O14757 1/20 0.48
▸ IKBKB O14920 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1673441 0.93 ALK (0.52) KDRFLT1ALKPDGFRBFGFR1
SCHEMBL6722350 0.90 KDR (0.51) KDRFLT1ALKPDGFRBFGFR1
SCHEMBL2117957 0.82 MEN1 (0.46) KDRALKPDGFRBFGFR1KIT
SCHEMBL2114496 0.81 LRRK2 (0.42) KDRALKPDGFRBFGFR1FLT3
SCHEMBL5642412 0.80 MEN1 (0.42) KDRFLT1ALKPDGFRBFGFR1
SCHEMBL6734453 0.80 LRRK2 (0.41) KDRFLT1ALKPDGFRBFGFR1
SCHEMBL6725660 0.79 ALK (0.52) KDRFLT1ALKPDGFRBFGFR1
SCHEMBL722802 0.79 ALK (0.52) KDRFLT1ALKPDGFRBFGFR1
SCHEMBL2114228 0.78 SRC (0.45) KDRALKPDGFRBFGFR1FLT3
SCHEMBL2113633 0.78 MEN1 (0.41) KDRFLT1ALKPDGFRBFGFR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040152759-A1 Combination administration of an indolinone with a chemotherapeutic agent for cell proliferation disorders SUGEN, INC. 2004-08-05 — — US claimed
US-20040152759-A1 Combination administration of an indolinone with a chemotherapeutic agent for cell proliferation disorders SUGEN, INC. 2004-08-05 — — US disclosed
US-20030130280-A1 Treatment of acute myeloid leukemia with indolinone compounds SUGEN, INC. 2003-07-10 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040152759-A1 Combination administration of an indolinone with a chemotherapeutic agent for cell proliferation disorders MKI67, CCNA1, CCNI KDR 3687/4885FLT1 2177/4885ALK 4375/4885
US-20030130280-A1 Treatment of acute myeloid leukemia with indolinone compounds FLT3, FLI1, MCL1 KDR 71/4885FLT1 6/4885ALK 110/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback